Estrogen for Microvascular Function
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to understand how long-term estrogen use affects blood vessels in healthy adults. Researchers will divide participants into groups based on their past use of hormone treatments like estrogen and progestin, or no use at all. They will compare blood vessel function among these groups using tests such as blood draws and scans. This study is ideal for females aged 18-40 who have been on specific hormone treatments or none for the specified durations and have controlled blood pressure and limited cardiovascular risk factors. As an unphased study, this trial offers participants the chance to contribute to foundational research that may enhance future hormone therapies.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it excludes those on medications that could affect heart and blood vessel control. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that hormone treatments like estrogen and progestin have been studied for their safety. Using estrogen with progestin can slightly increase the risk of certain health issues, such as blood clots and breast cancer. However, adding progestin reduces the risk of endometrial cancer, which can be a concern for women taking only estrogen.
When using progestin alone, some studies have mentioned side effects like irregular bleeding, but this usually improves over time. Progestin alone can also slightly increase the risk of breast cancer.
Overall, while some risks exist, many women use these treatments safely, especially with a doctor's guidance. It's important to consider these risks and benefits and discuss any concerns with a healthcare provider.12345Why are researchers excited about this trial?
Researchers are excited about exploring estrogen and progestin treatments because they might offer new insights into improving microvascular function, particularly in females. Unlike current treatments that don't specifically target microvascular health, these hormone therapies could potentially enhance blood vessel function and improve overall cardiovascular health. By examining the effects of continuous estrogen/progestin, continuous progestin, and no hormone treatment, researchers aim to uncover how these hormones influence microvascular systems, paving the way for more targeted and effective therapies in the future.
What evidence suggests that this trial's treatments could be effective for blood vessel function?
This trial will compare different hormone therapy regimens. Research has shown that estrogen and progestin therapy, which participants in the "Continuous estrogen/progestin" arm may receive, can help manage menopause symptoms like hot flashes and night sweats. Studies have found that using estrogen and progestin together can help prevent bone loss, a common issue during menopause. However, this combination might slightly raise the risk of breast cancer.
Participants in the "Continuous progestin" arm will receive progestin alone. Research indicates that progestin might lower the risk of endometrial cancer, which affects the lining of the uterus. Some studies suggest that progestin can improve treatment responses, but there is a higher risk of blood clots with hormone therapies. Considering these benefits and risks is important when evaluating hormone therapy options.46789Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo procedures to assess blood vessel function, including blood draw, imaging, and catheter placement
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Estrogen
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Females who have not had continuous estrogen treatment for a minimum of 5 years.
Females who have had continuous progestin treatment for a minimum of 1 year.
Females who have had continuous estrogen/progestin treatment for a minimum of 1 year.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor
Citations
Hormone Replacement Therapy - StatPearls - NCBI Bookshelf
Hormone replacement therapy (HRT) replenishes women with ovarian hormones diminished during the natural menopausal transition to alleviate associated symptoms.
2.
journals.lww.com
journals.lww.com/menopausejournal/fulltext/2024/05000/use_of_menopausal_hormone_therapy_beyond_age_65.3.aspxUse of menopausal hormone therapy beyond age 65 years ...
For the use of estrogen and progestogen combo-therapy, both E+ progestin and E+ progesterone were associated with increased risk of breast cancer by 10%-19 ...
Rethinking Menopausal Hormone Therapy: For Whom, ...
Systemic ET represents an effective treatment for VMS and other menopause symptoms, including genitourinary syndrome of menopause (GSM). Oral ...
Effect of continuous and sequential oral estrogen ...
The aim of the present study was to determine whether assignment to continuous estrogen–progestin therapy is more effective in protecting against bone loss.
5.
npr.org
npr.org/sections/health-shots/2024/05/01/1248525256/hormones-menopause-hormone-therapy-hot-flashesHormones for menopause are safe, study finds. ...
We found hormone therapy has low risk of adverse events and is safe for treating bothersome hot flashes, night sweats and other menopausal symptoms.
Risks, Benefits, and Treatment Modalities of Menopausal ...
Results showed an increased risk of 9%-17% of AD in women on either estrogen-progesterone therapy or estrogen therapy alone (OR: 1.17, 95%CI: ...
Menopausal Hormone Therapy and Cancer Risk
Adding a progestin to the estrogen lowers the risk of endometrial cancer back to normal. Because of this, EPT is given to women who still have a ...
Risks and Benefits of Estrogen Plus Progestin in Healthy ...
Conclusions Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy ...
Contemporary menopausal hormone therapy and risk of ...
A higher risk of venous thromboembolism was observed for oral continuous oestrogen-progestin therapy (1.61, 1.35 to 1.92), sequential therapy ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.